Glucose control is associated with patient survival in diabetic patients after renal transplantation

Transplantation

Volumn 89, Issue 5, 2010, Pages 612-619

  Wiesbauer, Franz ^a   Heinze, Georg ^a   Regele, Heinz ^a   Hörl, Walter H ^a   Schernthaner, Gerit H ^a   Schwarz, Christoph ^b   Kainz, Alexander ^b   Kramar, Reinhard ^c   Oberbauer, Rainer ^b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KH Elisabethinen ^*  (Austria)

^c Austrian Dialysis and Transplant Registry   (Austria)

Author keywords

Cohort study; Glycemic control; Graft failure; Mortality; Renal transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC DIET; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARAMETER; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; EUROPE; GRAFT SURVIVAL; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77949407776     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c6ffa4     Document Type: Article

References (42)

1. Microvascular and acute complications in IDDM patients: The EURODIAB IDDM Complications Study. Diabetologia 1994; 37: 278.
2. Krolewski AS, Warram JH, Christlieb AR, et al. The changing natural history of nephropathy in type I diabetes. Am J Med 1985; 78: 785.
3. Steffes MW, Sutherland DE, Goetz FC, et al. Studies of kidney and muscle biopsy specimens from identical twins discordant for type I diabetes mellitus. N Engl J Med 1985; 312: 1282.
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977.
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes (UKPDS 33).UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837.
6. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49: S12.
7. Barbosa J, Steffes MW, Sutherland DE, et al. Effect of glycemic control on early diabetic renal lesions. A 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients. JAMA 1994; 272: 600.
8. Racusen LC, Solez K, Colvin RB, et al. The Banff '97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
9. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
10. Churg J, Sobin LH. Benign nephrosclerosis. In: Churg J, eds. Renal disease\Classification and atlas of glomerular diseases, vol.1. Tokyo, Igaku-Shoin 1982, pp 211.
11. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343.
12. Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator Am Stat 2005; 59: 301.
13. Cox DR. Regression models and life-tables (with discussion). J Roy Stat Soc B 1972; 34: 187.
14. Bursac Z,Gauss H, WilliamsK, etal. A purposeful selectionofvariables macro for logistic regression. SAS Institute Inc 2007 Proceedings of the SAS Global Forum 2007 conference Cary, NC: SAS Institute Inc. (paper 173) 2007.
15. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550.
16. Bodnar LM, Davidian M, Siega-Riz AM, et al. Marginal structural models for analyzing causal effects of time-dependent treatments: An application in perinatal epidemiology. Am J Epidemiol 2004; 159: 926.
17. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11: 561.
18. Kasiske BL, Vazquez MA, Harmon WE,etal. Recommendations for the outpatient surveillanceof renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; (11 suppl 15): S1.
19. Morath C, Zeier M, Dohler B, et al. Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes. J Am Soc Nephrol 2008; 19: 1557.
20. Reddy KS, Stablein D, Taranto S, et al. Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure. Am J Kidney Dis 2003; 41: 464.
21. Thomas MC, Mathew TH, Russ GR, et al. Early peri-operative glycae-mic control and allograft rejection in patients with diabetes mellitus: A pilot study. Transplantation 2001; 72: 1321.
22. Troppmann C, Gillingham KJ, Benedetti E, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation 1995; 59: 962.
23. LaaksoM.Hyperglycemia and cardiovascular diseaseintype2diabetes. Diabetes 1999; 48: 937.
24. Ceriello A. Postprandial hyperglycemia and diabetes complications: Is it time to treat? Diabetes 2005; 54: 1.
25. Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin 2003; 19: 635
26. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999; 354: 617.
27. Balkau B,Shipley M,Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360.
28. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233.
29. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: The Hoorn Study. Diabetologia 1999; 42: 926.
30. Donahue RP, Abbott RD, Reed DM, et al. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987; 36: 689.
31. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577.
32. Lowe LP, Liu K, Greenland P, et al. Diabetes, asymptomatic hypergly-cemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997; 20: 163.
33. Temelkova-Kurktschiev TS, Koehler C, Henkel E, et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level.Diabetes Care2000; 23: 1830.
34. Ceriello A. The post-prandial state and cardiovascular disease: Relevance to diabetes mellitus. Diabetes Metab Res Rev 2000; 16: 125.
35. Ceriello A, Bortolotti N, Motz E, et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: The possible role of hyperglycemia. Metabolism 1999; 48: 1503.
36. Diwadkar VA, Anderson JW, Bridges SR, et al. Postprandial low-density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med 1999; 222: 178.
37. Giugliano D, Marfella R, Coppola L, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 1783.
38. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999; 34: 146.
39. Marfella R, Verrazzo G, Acampora R, et al. Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects. Am J Physiol 1995; 268: E1167.
40. Shige H,Ishikawa T, Suzukawa M, et al.Endothelium-dependent flow-mediated vasodilation in the postprandial state in type 2 diabetes mel-litus. Am J Cardiol 1999; 84: 1272.
41. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854.
42. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545.